RNA-seq profile of African American men with a clinically localized prostate cancer

Naoya Nagaya; Jeffrey Rosenfeld; Geun Taek Lee; Isaac Yi Kim

doi:10.1016/j.prnil.2020.11.002

RNA-seq profile of African American men with a clinically localized prostate cancer

Prostate Int. 2021 Sep;9(3):125-131. doi: 10.1016/j.prnil.2020.11.002. Epub 2020 Nov 19.

Authors

Naoya Nagaya¹, Jeffrey Rosenfeld², Geun Taek Lee¹, Isaac Yi Kim¹

Affiliations

¹ Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
² Pathology and Laboratory Medicine, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ, USA.

Abstract

Background: Prostate cancer in African American (AA) men has a poor prognosis. This study aimed to identify potential genetic risk factors for prostate cancer in AA men.

Methods: We used prostate cancer tissue from 61 patients who underwent radical prostatectomy. We compared somatic gene expression in Caucasian (CA) and AA men using RNA sequencing.

Results: By comparing the RNA-seq data obtained from prostate cancer tissue between AA and CA men, this study showed a significant difference in expression levels of 45 genes. Pathway analysis of 45 genes using Kyoto Encyclopedia of Genes and Genomesenrichment analysis revealed a neuroactive ligand-receptor interaction signal. In addition, the results of the Ingenuity Pathway Analysis showed pathways involved sphingosine-1-phosphate signaling. Furthermore, validating 45 genes in the The Cancer Genome Atlas (TCGA) Provisional cohort, cholinergic receptor muscarinic 3 expression level was significantly lower in AA than in CA men, and the results showed a significantly higher rate of biochemical recurrence in patients with low expression.

Conclusions: We identified genetic differences of clinically localized prostate cancer in AAs and CAs by RNA sequencing.

Keywords: African American; Caucasian; Prostate cancer; RNA-seq.